The design of flexible ciprofloxacin-loaded PLGA implants using a reversed phase separation/coacervation method

Park, Peter In Pyo; Makoid, Michael C.; Jonnalagadda, Sriramakamal

doi:10.1016/j.ejpb.2010.11.014

Cited by 9 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over the past few decades, a great quantity of different synthetic polymers such as polyurea, polyamide, polyurethane, polystyrene, and polyvinyl chloride have been used to prepare pesticide microcapsules. [19][20][21][22][23] Nevertheless, the applications of such polymer systems are greatly limited by the complex processes and the organic solvent residues. In addition, some active ingredients can be adsorbed by polymers via hydrophobic-lipophilic interactions, leading to a loss of bioactivity.…”

Section: Introductionmentioning

confidence: 99%

Preparation and characterization of double-shelled avermectin microcapsules based on copolymer matrix of silica–glutaraldehyde–chitosan

Zhang

et al. 2013

J. Mater. Chem. B

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Preparation and characterization of double-shelled avermectin microcapsules based on copolymer matrix of silica–glutaraldehyde–chitosan

Zhang

et al. 2013

J. Mater. Chem. B

View full text Add to dashboard Cite

“…Therefore, no comparison of the observed drug release of cipro with literature data for this special application is possible. Different working groups have prepared cipro or ciprofloxacin hydrochloride containing implants for the treatment of osteomyelitis or periodontitis based on different matrices like poly(DL)-lactide (PLA) [31], crosslinked high amylose starch [32], poly (epsilon-caprolactone) [33] or poly(lactide-co-glycolide) (PLGA) [34,35]. Recently, patient-specific, cipro-containing implants based on a matrix consisting of PLA, hydroxypropyl cellulose and microcrystalline cellulose for the treatment of bone defect diseases have been produced by Cui et al [36] who report a limited burst effect for 3D-printed implants.…”

Section: Drug Releasementioning

confidence: 99%

Individualized, Additively Manufactured Drug-Releasing External Ear Canal Implant for Prevention of Postoperative Restenosis: Development, In Vitro Testing, and Proof of Concept in an Individual Curative Trial

et al. 2022

View full text Add to dashboard Cite

Postoperative restenosis in patients with external ear canal (EEC) atresia or stenosis is a common complication following canaloplasty. Our aim in this study was to explore the feasibility of using a three dimensionally (3D)-printed, patient-individualized, drug ((dexamethasone (DEX)), and ciprofloxacin (cipro))-releasing external ear canal implant (EECI) as a postoperative stent after canaloplasty. We designed and pre-clinically tested this novel implant for drug release (by high-performance liquid chromatography), biocompatibility (by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay), bio-efficacy (by the TNF-α (tumor necrosis factor-alpha)-reduction test (DEX) and inhibition zone test (for cipro)), and microbial contamination (formation of turbidity or sediments in culture medium). The EECI was implanted for the first time to one patient with a history of congenital EEC atresia and state after three canaloplasties due to EEC restenosis. The preclinical tests revealed no cytotoxic effect of the used materials; an antibacterial effect was verified against the bacteria Staphylococcus aureus and Pseudomonas aeruginosa, and the tested UV-irradiated EECI showed no microbiological contamination. Based on the test results, the combination of silicone with 1% DEX and 0.3% cipro was chosen to treat the patient. The EECI was implantable into the EEC; the postoperative follow-up visits revealed no otogenic symptoms or infections and the EECI was explanted three months postoperatively. Even at 12 months postoperatively, the EEC showed good epithelialization and patency. Here, we report the first ever clinical application of an individualized, drug-releasing, mechanically flexible implant and suggest that our novel EECI represents a safe and effective method for postoperatively stenting the reconstructed EEC.

show abstract

“…Vancomycin is a frequently used antibiotic against infections caused by MRSA [ 8 ]. Local antibiotic delivery systems [ 9 , 10 ] are proposed to control IRO safely and efficiently as parenteral administration of high doses of vancomycin for long durations may lead to some effects [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Vancomycin containing PLLA/β-TCP controls experimental osteomyelitis in vivo

et al. 2014

View full text Add to dashboard Cite

BackgroundImplant-related osteomyelitis (IRO) is recently controlled with local antibiotic delivery systems to overcome conventional therapy disadvantages. In vivo evaluation of such systems is however too little.Questions/purposesWe asked whether vancomycin (V)-containing poly-l-lactic acid/β-tricalcium phosphate (PLLA/β-TCP) composites control experimental IRO and promote bone healing in vivo.MethodsFifty-six rats were distributed to five groups in this longitudinal controlled study. Experimental IRO was established at tibiae by injecting methicillin-resistant Staphylococcus aureus (MRSA) suspensions with titanium particles in 32 rats. Vancomycin-free PLLA/β-TCP composites were implanted into the normal and infected tibiae, whereas V-PLLA/β-TCP composites and coated (C)-V-PLLA/β-TCP composites were implanted into IRO sites. Sham-operated tibiae established the control group. Radiological and histological scores were quantified with microbiological findings on weeks 1 and 6.ResultsIRO is resolved in the CV- and the V-PLLA/β-TCP groups but not in the PLLA/β-TCP group. MRSA was not isolated in the CV- and the V-PLLA/β-TCP groups at all times whereas the bacteria were present in the PLLA/β-TCP group. Radiological signs secondary to infection are improved from 10.9 ± 0.9 to 3.0 ± 0.3 in the V-PLLA/β-TCP group but remained constant in the PLLA/β-TCP group. Histology scores are improved from 24.7 ± 6.5 to 17.6 ± 4.8 and from 27.6 ± 7.9 to 32.4 ± 8.9 in the CV-PLLA/β-TCP and the V-PLLA/β-TCP groups, respectively. New bone was formed in all the PLLA/β-TCP group at weeks 1 and 6.ConclusionsCV- and V-PLLA/β-TCP composites controlled experimental IRO and promoted bone healing.Clinical relevanceCV- and V-PLLA/β-TCP composites have the potential of controlling experimental IRO and promoting bone healing.

show abstract

The design of flexible ciprofloxacin-loaded PLGA implants using a reversed phase separation/coacervation method

Cited by 9 publications

References 23 publications

Preparation and characterization of double-shelled avermectin microcapsules based on copolymer matrix of silica–glutaraldehyde–chitosan

Preparation and characterization of double-shelled avermectin microcapsules based on copolymer matrix of silica–glutaraldehyde–chitosan

Individualized, Additively Manufactured Drug-Releasing External Ear Canal Implant for Prevention of Postoperative Restenosis: Development, In Vitro Testing, and Proof of Concept in an Individual Curative Trial

Vancomycin containing PLLA/β-TCP controls experimental osteomyelitis in vivo

Contact Info

Product

Resources

About